AveXis Inc. (NASDAQ:AVXS)’s share price traded down 3.4% during mid-day trading on Wednesday . The stock traded as low as $33.15 and last traded at $35.34, with a volume of 510,877 shares changing hands. The stock had previously closed at $36.57.

Several equities analysts recently commented on AVXS shares. Zacks Investment Research upgraded AveXis from a “sell” rating to a “hold” rating in a research note on Friday, June 24th. Chardan Capital reiterated a “buy” rating and issued a $60.00 price objective on shares of AveXis in a research note on Friday, August 12th. Jefferies Group downgraded AveXis from a “buy” rating to a “hold” rating and upped their price objective for the company from $39.00 to $42.00 in a research note on Wednesday, June 22nd. They noted that the move was a valuation call. Wells Fargo & Co. started coverage on AveXis in a research note on Friday, July 15th. They issued a “market perform” rating on the stock. Finally, Goldman Sachs Group Inc. upped their price objective on AveXis from $28.00 to $47.00 and gave the company a “buy” rating in a research note on Friday, May 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $45.40.

The stock has a 50 day moving average of $37.33 and a 200-day moving average of $32.22. The company’s market cap is $813.28 million.

AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, August 11th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.77) by $0.09. Analysts forecast that AveXis Inc. will post ($3.38) EPS for the current year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.